The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-118

The question is does MT have any more information then the rest of us.
The answer I would think would be one would expect him to have if not more information but at least a greater understanding of how the results will look.
He has access to the researchers and one would think this indirectly gives him access to how the patients are still going.
This gives him a great responsibility which he must or should use with great care in a way not to give unrealistic expectations to shareholders.
Some might say he is not acting as a company representative but posting stuff via Linkin but in rhis day and age anything he post reflects on PAA.
Now I gave this warning prior to Elanco decision and during the canine trial and also covid testing.
Always be prepared for bad news, make up your own mind on how much risk you are willing to accept.
Remember we had gotten great data before and the sp dropped.